

America's biopharmaceutical companies continue to battle a once in a generation challenge by delivering safe and effective COVID-19 treatments and vaccines to American patients and other countries around the globe. As the world remains impacted by the COVID-19 pandemic, the biopharmaceutical industry is working around-the-clock to research, develop and manufacture treatments and vaccines to fight this virus.

Our industry has achieved this success in part by:

LEVERAGING EXPERTISE

Biopharmaceutical research companies utilized decades of experience from past infectious disease outbreaks and new platform technologies to dramatically streamline and accelerate the R&D timeline for COVID-19 vaccines and treatments.

PhRMA member companies have:

- Scrutinized existing research products
- Reviewed prior infectious disease portfolios
- Harnessed new platform technologies
- Applied decades of infectious disease and vaccine research and manufacturing expertise
- Partnered together to increase manufacturing capacity
- Continued to explore R&D of new treatments and vaccines against COVID-19
- Delivered nearly 12 billion vaccines globallyⁱ


EMBRACING PARTNERSHIPS

The COVID-19 pandemic has demonstrated the importance of public-private sector collaboration at the state, national and international levels.

America's biopharmaceutical companies have joined forces to fight COVID-19 and are collaborating with hundreds of key health stakeholders to help diagnose and develop therapeutics and vaccines and ramp up manufacturing to meet global needs.


Prior to authorization, biopharmaceutical companies proactively planned and built manufacturing capacity to ensure that once COVID-19 vaccines and treatments were authorized or approved by the FDA, distribution could occur rapidly.ⁱⁱ

The biopharmaceutical industry continues to work with a range of public and private stakeholders to develop innovative COVID-19 treatments and vaccines. This engagement has been facilitated in part by robust intellectual property policies.



Biopharmaceutical companies are at the heart of a robust U.S. research and development ecosystem that develops more innovative medicines than any other country in the world. In part due to this ecosystem, COVID-19 treatments and vaccines have been brought to patients in record time while maintaining the same standards for safety and efficacy. As we look to the importance of biopharmaceutical innovation, now more than ever, it is critical that both public and private assets can be brought to bear in addressing critical diseases such as COVID-19.

BY THE NUMBERS: OUR PROGRESS AGAINST COVID-19



As of February 4, 2022 – PhRMA.org/Coronavirus

Although our industry has achieved historic success against this virus, we know our work is not done. We continue to address emerging variants, further enhance the manufacturing process and pursue other innovations, like reducing the need for cold storage. We also need to embrace policies that support patient access and affordability without undermining the development of tomorrow's lifesaving medicines. Advancing the research and development of new vaccines and treatments will not only improve our efforts against this pandemic, but also better prepare us for the next crisis.

"We always need a pharmaceutical partner. I can't think of a vaccine, even one in which we've put substantial intellectual and resource input, that was brought to the goal line without a partnership with industry." – NIAID Director Dr. Anthony Fauci

¹<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> - As of February 2022

²<https://phrma.org/coronavirus/working-together-to-fight-covid-19-vaccine-manufacturing-collaborations>